211 related articles for article (PubMed ID: 30833139)
1. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer.
Li R; Spiess PE; Gilbert SM; Necchi A
Eur Urol; 2019 Jul; 76(1):4-6. PubMed ID: 30833139
[TBL] [Abstract][Full Text] [Related]
2. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
[TBL] [Abstract][Full Text] [Related]
3. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.
Necchi A; Raggi D; Gallina A; Madison R; Colecchia M; Lucianò R; Montironi R; Giannatempo P; Farè E; Pederzoli F; Bandini M; Bianchi M; Colombo R; Gandaglia G; Fossati N; Marandino L; Capitanio U; Dehò F; Ali SM; Chung JH; Ross JS; Salonia A; Briganti A; Montorsi F
Eur Urol; 2020 Apr; 77(4):439-446. PubMed ID: 31708296
[TBL] [Abstract][Full Text] [Related]
4. Perioperative systemic therapy for bladder cancer.
Eulitt PJ; Bjurlin MA; Milowsky MI
Curr Opin Urol; 2019 May; 29(3):220-226. PubMed ID: 30855376
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
6. Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.
Miyake M; Hori S; Ohnishi S; Toritsuka M; Fujii T; Shimizu T; Owari T; Morizawa Y; Gotoh D; Itami Y; Nakai Y; Anai S; Torimoto K; Tanaka N; Fujimoto K
Cancer Sci; 2019 Oct; 110(10):3315-3327. PubMed ID: 31385407
[TBL] [Abstract][Full Text] [Related]
7. The promise and challenges of neoadjuvant immunotherapy in the management of non-metastatic muscle-invasive bladder cancer.
Janisch F; Rink M; Shariat SF
BJU Int; 2020 Jun; 125(6):753-755. PubMed ID: 32011069
[No Abstract] [Full Text] [Related]
8. Recent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma.
Balar AV
Oncology (Williston Park); 2019 Apr; 33(4):132-6. PubMed ID: 30990565
[No Abstract] [Full Text] [Related]
9. Emerging role of checkpoint inhibition in localized bladder cancer.
Singh P; Black P
Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
[TBL] [Abstract][Full Text] [Related]
10. Complete response to anti-PD-L1 antibody in a metastatic bladder cancer associated with novel MSH4 mutation and microsatellite instability.
Yang Y; Jain RK; Glenn ST; Xu B; Singh PK; Wei L; Hu Q; Long M; Hutson N; Wang J; Battaglia S; George S
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221012
[TBL] [Abstract][Full Text] [Related]
11. Post-chemotherapy PD-L1 expression correlates with clinical outcomes in Japanese bladder cancer patients treated with total cystectomy.
Noro D; Hatakeyama S; Yoneyama T; Hashimoto Y; Koie T; Kawaguchi T; Ohyama C
Med Oncol; 2017 Jun; 34(6):117. PubMed ID: 28500617
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in non-metastatic urothelial cancer: back to the 'future'.
Darling HS; Bellmunt J
Expert Opin Biol Ther; 2019 Jul; 19(7):685-695. PubMed ID: 31046476
[TBL] [Abstract][Full Text] [Related]
13. [Immuno-oncological approaches in the perioperative therapy of muscle invasive bladder cancer].
Schmid SC; Koll FJ; Beckert F; Seitz AK
Urologe A; 2020 Jul; 59(7):790-796. PubMed ID: 32472221
[TBL] [Abstract][Full Text] [Related]
14. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
15. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
Teo MY; Rosenberg JE
Urol Clin North Am; 2018 May; 45(2):287-295. PubMed ID: 29650143
[TBL] [Abstract][Full Text] [Related]
16. Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer.
Bandini M; Ross JS; Raggi D; Gallina A; Colecchia M; Lucianò R; Giannatempo P; Farè E; Pederzoli F; Bianchi M; Colombo R; Gandaglia G; Fossati N; Marandino L; Capitanio U; Deho' F; Ali SM; Madison R; Chung JH; Salonia A; Briganti A; Montorsi F; Necchi A
J Natl Cancer Inst; 2021 Jan; 113(1):48-53. PubMed ID: 32516377
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
18. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
Pietzak EJ; Bagrodia A; Cha EK; Drill EN; Iyer G; Isharwal S; Ostrovnaya I; Baez P; Li Q; Berger MF; Zehir A; Schultz N; Rosenberg JE; Bajorin DF; Dalbagni G; Al-Ahmadie H; Solit DB; Bochner BH
Eur Urol; 2017 Dec; 72(6):952-959. PubMed ID: 28583311
[TBL] [Abstract][Full Text] [Related]
19. Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?
Pederzoli F; Bandini M; Raggi D; Marandino L; Basile G; Alfano M; Colombo R; Salonia A; Briganti A; Gallina A; Montorsi F; Necchi A
Eur Urol; 2021 Sep; 80(3):319-322. PubMed ID: 34053782
[TBL] [Abstract][Full Text] [Related]
20. Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab.
Vennapusa B; Baker B; Kowanetz M; Boone J; Menzl I; Bruey JM; Fine G; Mariathasan S; McCaffery I; Mocci S; Rost S; Smith D; Dennis E; Tang SY; Damadzadeh B; Walker E; Hegde PS; Williams JA; Koeppen H; Boyd Z
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):92-100. PubMed ID: 29346180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
